Core Laboratories Inc.
CLB
$16.45
$0.342.11%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 517.50M | 517.38M | 517.80M | 523.85M | 522.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 517.50M | 517.38M | 517.80M | 523.85M | 522.82M |
| Cost of Revenue | 414.27M | 416.17M | 415.40M | 420.52M | 415.84M |
| Gross Profit | 103.23M | 101.20M | 102.39M | 103.33M | 106.98M |
| SG&A Expenses | 42.70M | 40.65M | 40.46M | 38.59M | 38.09M |
| Depreciation & Amortization | 14.65M | 14.73M | 14.83M | 14.95M | 15.16M |
| Other Operating Expenses | -1.53M | -2.16M | -2.90M | -2.32M | -2.47M |
| Total Operating Expenses | 470.09M | 469.40M | 467.79M | 471.75M | 466.63M |
| Operating Income | 47.41M | 47.98M | 50.01M | 52.10M | 56.20M |
| Income Before Tax | 44.22M | 42.64M | 42.85M | 46.19M | 45.61M |
| Income Tax Expenses | 11.49M | 12.42M | 14.12M | 14.03M | 18.49M |
| Earnings from Continuing Operations | 32.73 | 30.21 | 28.73 | 32.15 | 27.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -607.00K | -581.00K | -706.00K | -753.00K | -922.00K |
| Net Income | 32.12M | 29.63M | 28.03M | 31.40M | 26.20M |
| EBIT | 47.41M | 47.98M | 50.01M | 52.10M | 56.20M |
| EBITDA | 62.06M | 62.71M | 64.83M | 67.05M | 71.36M |
| EPS Basic | 0.69 | 0.63 | 0.59 | 0.67 | 0.56 |
| Normalized Basic EPS | 0.45 | 0.46 | 0.48 | 0.50 | 0.54 |
| EPS Diluted | 0.67 | 0.62 | 0.59 | 0.66 | 0.55 |
| Normalized Diluted EPS | 0.45 | 0.46 | 0.47 | 0.49 | 0.53 |
| Average Basic Shares Outstanding | 187.44M | 188.10M | 188.38M | 188.46M | 188.25M |
| Average Diluted Shares Outstanding | 188.99M | 189.73M | 190.11M | 191.04M | 190.82M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 5.83% | 6.33% | 6.70% | 5.97% | 7.15% |